Block listing Interim Review

Report this content

3 June 2019 15:00 BST

Block Listing Six Monthly Return

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 3 June 2019

Name of applicant: ASTRAZENECA PLC
Name of scheme: ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME
Period of return: From: 1 December 2018 To: 31 May 2019
Balance of unallotted securities under scheme(s) from previous return: 1,827,017
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 578,981
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1,248,036


Name of contact: CAMILLA WISEMAN
Telephone number of contact: 020 3749 5000

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations    
Gonzalo Viña   +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharma +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
     
Investor Relations    
Thomas Kudsk Larsen   +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharma (cardiovascular; metabolism) +44 203 749 5711
Nick Stone BioPharma (respiratory; renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Kretzmann Corporate access, retail investors +44 203 749 5824
US toll-free   +1 866 381 72 77

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com

Subscribe

Documents & Links